Serum glutamate levels correlate with gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells

Clinical Cancer Research

Volumn 18, Issue 21, 2012, Pages 5888-5901

  Koochekpour, Shahriar ^a   Majumdar, Sunipa ^a   Azabdaftari, Gissou ^a   Attwood, Kristopher ^a,b   Scioneaux, Ray ^a   Subramani, Dhatchayini ^a   Manhardt, Charles ^a   Lorusso, Giovanni D ^c   Willard, Stacey S ^a   Thompson, Hillary ^d   Shourideh, Mojgan ^a   Rezaei, Katayoon ^f   Sartor, Oliver ^e   Mohler, James L ^a,h,i   Vessella, Robert L ^g  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CREATININE; GAMMA HISTONE H2AX; GLUTAMIC ACID; HISTONE H2AX; METABOTROPIC RECEPTOR 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; AMINO ACID BLOOD LEVEL; APOPTOSIS; ARTICLE; ASSAY; BOYDEN CHAMBER ASSAY; CANCER CELL; CANCER STAGING; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CAUCASIAN; CELL GROWTH; CELL INVASION; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIUM CELL; GLEASON SCORE; GROUPS BY AGE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUMINAL ACINAR EPITHELIAL CELL; MALE; METASTATIC CASTRATE RESISTANT PROSTATE CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RACE DIFFERENCE;

ADULT; AFRICAN AMERICANS; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, METABOTROPIC GLUTAMATE; RILUZOLE;

EID: 84868560533     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1308     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Platz EA, Rimm EB, Willett WC, Kantoff PW, Giovannucci E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92:2009-17. (Pubitemid 32045897)
3. Trock BJ. Application of metabolomics to prostate cancer. Urol Oncol 2011;29:572-81.
4. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991;18:25-46.
5. Komuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science 1993;260:95-7. (Pubitemid 23122752)
6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
7. Koppenal W, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev 2011;11:325-37.
8. Newsholme EA, Crabtree B, Ardawi MS. Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q J Exp Physiol 1985;70:473-89. (Pubitemid 16255147)
9. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
10. Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, et al. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008;7:600-11. (Pubitemid 351472469)
11. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
12. Young VR, Ajami AM. Glutamate: an amino acid of particular distinction. J Nutr 2000;130(Suppl 4):892S-900S. (Pubitemid 30173612)
13. Monaghan DT, Bridges RJ, Cotman CW. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 1989;29:365-402. (Pubitemid 19107360)
14. Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell melanoma Res 2008;21:368-78.
15. Shin SS, Martino JJ, Chen S. Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology 2008;55:396-402.
16. Takano T, Lin JH, Arcuino G, Gao Q, Yang J, Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat Med 2001;7:1010-5. (Pubitemid 32937380)
17. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A 2001;98:6372-7. (Pubitemid 32488244)
18. Chen S, Zhu H, Wetzel WJ, Philbert MA. Spontaneous melanocytosis in transgenic mice. J Invest Dermatol 1996;106:1145-51. (Pubitemid 26153519)
19. Zhu H, Reuhl K, Zhang X, Botha R, Ryan K, Wei J, et al. Development of heritable melanoma in transgenic mice. J Invest Dermatol 1998;110:247-52. (Pubitemid 28144599)
20. Pissimissis N, Papageorgiou E, Lembessis P, Armakolas A, Koutsilieris M. The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res 2009;29:371-7.
21. Schroeder JC, Bensen JT, Su LJ, Mishel M, Ivanova A, Smith GJ, et al. The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. Prostate 2006;66:1162-76. (Pubitemid 44175339)
22. Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, et al. Serum prosaposin levels are increased in patients with advanced prostate cancer. Prostate 2012;72:253-69.
23. Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, et al. Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 2005;44:351-64. (Pubitemid 41476786)
24. Carroll FY, Stolle A, Beart PM, Voerste A, Brabet I, Mauler F, et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol 2001;59:965-73. (Pubitemid 32381574)
25. Hu S, Delorme N, Liu Z, Liu T, Velasco-Gonzalez C, Garai J, et al. Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol Cancer 2010;9:30.
26. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000;275:9390-5. (Pubitemid 30185164)
27. Wasa M, Bode BP, Abcouwer SF, Collins CL, Tanabe KK, Souba WW. Glutamine as a regulator of DNA and protein biosynthesis in human solid tumor cell lines. Ann Surg 1996;224:189-97. (Pubitemid 26272066)
28. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-51. (Pubitemid 126447436)
29. Barinka C, Rinnová M, Sácha P, Rojas C, Majer P, Slusher BS, et al. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 2002;80:477-87. (Pubitemid 36383031)
30. Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 2011;71:281-8.
31. Aleman M, Milbank A, Harsch KM, Detore N, Klein E, Heston W. Expression of metabotropic glutamate receptors and its potential signaling through prostate specific membrane antigen. Proc Am Assoc Cancer Res 2004;45:Abstract # 5188.
32. Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 2005;11:3288-95. (Pubitemid 40627877)
33. Kalariti N, Lembessis P, Papageorgiou E, Pissimissis N, Koutsilieris M. Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells. J Musculoskelet Neuronal Interact 2007;7:113-8. (Pubitemid 47249000)
34. Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Joung MK, et al. Clinical outcome of catheter salvage in neutropenic cancer patients with catheter-related infection. Scand J Infect Dis 2011;43:258-63.
35. Ragin CC, Langevin S, Rubin S, Taioli E. Review of studies on metabolic genes and cancer in populations of African descent. Genet Med 2010;12:12-8.
36. Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet 2003;34:108-12. (Pubitemid 36548800)
37. Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS, et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 2007;67:2298-305. (Pubitemid 46424250)
38. Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA, et al. The glutamate release inhibitor riluzole decreases migration, invasion, and proliferation of melanoma cells. J Invest Dermatol 2010;130:2240-9.
39. Speyer CL, Smith JS, Banda M, Devries JA, Mekani T, Gorski DH. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat 2012;132:565-73.
40. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas H, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;643892-9.
41. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005;24:6314-22. (Pubitemid 43080054)